Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
ConditionCommunity Acquired Pneumonia (CAP)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Maryland, Baltimore
About this trial
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\>
Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Eligibility criteria
Qualifiers
Evaluated in the emergency department or within 72 hours of hospitalization
Prescribed Ceftriaxone for community-acquired pneumonia
Disqualifiers
Planned or present admission to an intensive care unit
Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
Trial design
Treatments tested in this trial
- Ceftriaxone 1 gram daily
- Ceftriaxone 2 grams daily
Treatment groups
430 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov